Aurinia Pharmaceuticals Inc. (AUPH)Â
NASDAQ$8.46
Market Cap
$1.16B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
22 of 919
Rank in Industry
17 of 523
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
AUPH Insider Trading Activity
AUPH Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $23,535,126 | 6 | 25 |
Sells | $6,252,184 | 18 | 75 |
Related Transactions
| TANG KEVIN | director | 6 | $23.54M | 0 | $0 | $23.54M |
| Balakrishnan Brinda | director | 0 | $0 | 1 | $2,985 | $-2,985 |
| Jayne David R.W. | director | 0 | $0 | 1 | $28,390 | $-28,390 |
| Billen Daniel | director | 0 | $0 | 1 | $30,146 | $-30,146 |
| Leversage Jill | director | 0 | $0 | 1 | $32,201 | $-32,201 |
| MacKay-Dunn R. Hector | director | 0 | $0 | 1 | $32,316 | $-32,316 |
| Bailey Jeffrey Allen | director | 0 | $0 | 1 | $38,416 | $-38,416 |
| Smith Karen L. | director | 0 | $0 | 1 | $44,182 | $-44,182 |
| Habig Scott Michael | Chief Commercial Officer | 0 | $0 | 1 | $96,902 | $-96,902 |
| Keenan Greg | Chief Medical Officer | 0 | $0 | 2 | $166,262 | $-166,262 |
| Miller Joseph M | Chief Financial Officer | 0 | $0 | 2 | $939,612 | $-939,612 |
| Robertson Stephen P. | EVP, General Counsel | 0 | $0 | 2 | $975,223 | $-975,223 |
| Donley Matthew Maxwell | Chief Operating Officer | 0 | $0 | 2 | $994,425 | $-994,425 |
| Greenleaf Peter | Chief Executive Officer | 0 | $0 | 2 | $2.87M | $-2.87M |
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Insider Activity of Aurinia Pharmaceuticals Inc.
Over the last 12 months, insiders at Aurinia Pharmaceuticals Inc. have bought $23.54M and sold $6.25M worth of Aurinia Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Aurinia Pharmaceuticals Inc. have bought $6.2M and sold $13.83M worth of stock each year.
Highest buying activity among insiders over the last 12 months: TANG KEVIN (director) — $23.54M.
The last purchase of 748,038 shares for transaction amount of $5.95M was made by TANG KEVIN (director) on 2025‑03‑04.
List of Insider Buy and Sell Transactions, Aurinia Pharmaceuticals Inc.
| 2025-03-07 | Sale | Keenan Greg | Chief Medical Officer | 8,305 0.0061% | $8.23 | $68,350 | +2.39% | |
| 2025-03-04 | Sale | Greenleaf Peter | Chief Executive Officer | 164,947 0.1174% | $7.92 | $1.31M | +2.97% | |
| 2025-03-04 | Sale | Donley Matthew Maxwell | Chief Operating Officer | 58,991 0.042% | $7.92 | $467,209 | +2.97% | |
| 2025-03-04 | Sale | Miller Joseph M | Chief Financial Officer | 56,154 0.04% | $7.92 | $444,740 | +2.97% | |
| 2025-03-04 | Sale | Robertson Stephen P. | EVP, General Counsel | 57,607 0.041% | $7.92 | $456,247 | +2.97% | |
| 2025-03-04 | TANG KEVIN | director | 748,038 0.5348% | $7.96 | $5.95M | +2.97% | ||
| 2025-03-03 | Sale | Greenleaf Peter | Chief Executive Officer | 195,593 0.1432% | $8.00 | $1.56M | +4.14% | |
| 2025-03-03 | Sale | Donley Matthew Maxwell | Chief Operating Officer | 65,902 0.0483% | $8.00 | $527,216 | +4.14% | |
| 2025-03-03 | Sale | Miller Joseph M | Chief Financial Officer | 61,859 0.0453% | $8.00 | $494,872 | +4.14% | |
| 2025-03-03 | Sale | Robertson Stephen P. | EVP, General Counsel | 64,872 0.0475% | $8.00 | $518,976 | +4.14% | |
| 2025-03-03 | Sale | Keenan Greg | Chief Medical Officer | 12,239 0.009% | $8.00 | $97,912 | +4.14% | |
| 2025-03-03 | TANG KEVIN | director | 452,682 0.3318% | $8.01 | $3.63M | +4.14% | ||
| 2025-02-28 | TANG KEVIN | director | 399,280 0.2783% | $7.85 | $3.13M | +4.28% | ||
| 2024-12-09 | TANG KEVIN | director | 500,000 0.346% | $9.09 | $4.54M | -10.62% | ||
| 2024-12-06 | TANG KEVIN | director | 400,000 0.2812% | $9.01 | $3.6M | -8.57% | ||
| 2024-12-05 | TANG KEVIN | director | 300,000 0.2089% | $8.91 | $2.67M | -8.00% | ||
| 2024-11-11 | Sale | Bailey Jeffrey Allen | director | 4,557 0.0032% | $8.43 | $38,416 | -2.65% | |
| 2024-11-11 | Sale | Smith Karen L. | director | 5,241 0.0036% | $8.43 | $44,182 | -2.65% | |
| 2024-08-06 | Sale | Habig Scott Michael | Chief Commercial Officer | 18,249 0.0121% | $5.31 | $96,902 | +41.19% | |
| 2024-05-21 | Sale | Jayne David R.W. | director | 4,946 0.0036% | $5.74 | $28,390 | +28.98% |
Total: 92
*Gray background shows transactions not older than one year
Insider Historical Profitability
24.56%
| TANG KEVIN | director | 10029500 7.3027% | $84.85M | 6 | 0 | |
| Greenleaf Peter | Chief Executive Officer | 1788945 1.3026% | $15.13M | 1 | 5 | +37.58% |
| Donley Matthew Maxwell | Chief Operating Officer | 680465 0.4955% | $5.76M | 2 | 4 | +67.17% |
| Miller Joseph M | Chief Financial Officer | 577361 0.4204% | $4.88M | 1 | 5 | +37.58% |
| Robertson Stephen P. | EVP, General Counsel | 509276 0.3708% | $4.31M | 1 | 4 | <0.0001% |
| Habig Scott Michael | Chief Commercial Officer | 456338 0.3323% | $3.86M | 1 | 3 | +81.51% |
| Keenan Greg | Chief Medical Officer | 153484 0.1118% | $1.3M | 0 | 2 | |
| Jayne David R.W. | director | 44364 0.0323% | $375,319.44 | 0 | 2 | |
| Billen Daniel | director | 28141 0.0205% | $238,072.86 | 0 | 2 | |
| MacKay-Dunn R. Hector | director | 18595 0.0135% | $157,313.70 | 3 | 2 | +16.06% |
| Balakrishnan Brinda | director | 17523 0.0128% | $148,244.58 | 0 | 1 | |
| Bailey Jeffrey Allen | director | 13356 0.0097% | $112,991.76 | 0 | 1 | |
| Leversage Jill | director | 12918 0.0094% | $109,286.28 | 3 | 2 | <0.0001% |
| Smith Karen L. | director | 12672 0.0092% | $107,205.12 | 0 | 1 | |
| Knappertz Volker | EVP, Research and Development | 319128 0.2324% | $2.7M | 0 | 2 | |
| Solomons Neil | Chief Medical Officer | 90953 0.0662% | $769,462.38 | 0 | 10 | |
| Martin Michael Robert | Chief Business Officer | 89512 0.0652% | $757,271.52 | 1 | 15 | +80.79% |
| MILNE GEORGE M JR | director | 70000 0.051% | $592,200.00 | 3 | 0 | +0.28% |
| Huizinga Robert Bindert | EVP of Research | 69379 0.0505% | $586,946.34 | 0 | 6 | |
| Colao Massimilano | Chief Commercial Officer | 13495 0.0098% | $114,167.70 | 0 | 1 | |
| Hagan Joseph P | director | 11961 0.0087% | $101,190.06 | 0 | 2 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$8,217,280 | 112 | 46.33% | $1.17B | |
$54,590,806 | 65 | 21.84% | $1.23B | |
$1,101,324,300 | 58 | 37.37% | $1.23B | |
$571,084,134 | 44 | 4.33% | $898.59M | |
$100,002,191 | 42 | 21.48% | $1.3B | |
$530,111,731 | 35 | 8.67% | $1.12B | |
$61,752,931 | 34 | 14.31% | $866.68M | |
$7,598,498 | 27 | 34.68% | $1.14B | |
$169,638,586 | 22 | 30.82% | $1.19B | |
Aurinia Pharmaceuticals Inc. (AUPH) | $1,272,896 | 16 | 24.56% | $1.16B |
$50,317,062 | 13 | -3.69% | $870.41M | |
$278,247,340 | 12 | 58.08% | $914.74M | |
$43,198,628 | 12 | -0.10% | $1.2B | |
$2,834,855 | 9 | 34.92% | $1.17B | |
$1,229,547 | 7 | 11.98% | $1.05B | |
$46,235,722 | 6 | -31.77% | $869.54M | |
$7,605,533 | 5 | 17.10% | $941.77M | |
$16,839,601 | 5 | 87.76% | $1.24B | |
$5,000,000 | 1 | -22.84% | $1.22B |
AUPH Institutional Investors: Active Positions
| Increased Positions | 101 | +52.88% | 8M | +13.06% |
| Decreased Positions | 70 | -36.65% | 8M | -13.22% |
| New Positions | 39 | New | 3M | New |
| Sold Out Positions | 22 | Sold Out | 2M | Sold Out |
| Total Postitions | 222 | +16.23% | 58M | -0.16% |
AUPH Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $75,552.00 | 6.53% | 8.95M | -114,246 | -1.26% | 2024-12-31 |
| Tang Capital Management Llc | $71,145.00 | 6.15% | 8.43M | +1M | +16.6% | 2024-12-31 |
| Armistice Capital, Llc | $54,016.00 | 4.67% | 6.4M | -2M | -21.95% | 2024-12-31 |
| Nea Management Company, Llc | $33,505.00 | 2.9% | 3.97M | 0 | 0% | 2024-12-31 |
| State Street Corp | $24,628.00 | 2.13% | 2.92M | -27,021 | -0.92% | 2024-12-31 |
| Geode Capital Management, Llc | $14,891.00 | 1.29% | 1.76M | -1,975 | -0.11% | 2024-12-31 |
| Goldman Sachs Group Inc | $14,788.00 | 1.28% | 1.75M | -655,847 | -27.24% | 2024-12-31 |
| Vanguard Group Inc | $14,601.00 | 1.26% | 1.73M | +112,113 | +6.93% | 2024-12-31 |
| Morgan Stanley | $13,885.00 | 1.2% | 1.65M | +174,632 | +11.88% | 2024-12-31 |
| Nuveen Asset Management, Llc | $12,595.00 | 1.09% | 1.49M | +138,054 | +10.19% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.